|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2显示文摘Emerging and re-emerging RNA viruses occasionally cause epidemics and pandemics worldwide,such as the on-going outbreak of the novel coronavirus SARS-CoV-2.Herein,we identified two potent inhibitors of human DHODH,S312 and S416,with favorable drug-likeness and pharmacokinetic profiles,which all showed broad-spectrum antiviral effects against various RNA viruses,including influenza A virus,Zika virus,Ebola virus,and particularly against SARS-CoV-2.Notably,S416 is reported to be the most potent inhibitor so far with an EC5o of 17 nmol/L and an SI value of 10,505.88 in infec-ted cells.Our results are the first to validate that DHODH is an attractive host target through high antiviral efficacy in vivo and low virus replication in DHODH knock-out cells.This work demonstrates that both S312/S416 and old drugs(Leflunomide/Teriflunomide)with dual actions of antiviral and immuno-regulation may have clinical potentials to cure SARS-CoV-2 or other RNA viruses circulating worldwide,no matter such viruses are mutated or not. | Rui Xiong Leike Zhang Shiliang Li Yuan Sun Minyi Ding Yong Wang Yongliang Zhao Yan Wu Weijuan Shang Xiaming Jiang Jiwei Shan Zihao Shen Yi Tong Liuxin Xu Yu Chen Yingle Liu Gang Zou Dimitri Lavillete Zhenjiang Zhao Rui Wang Lili Zhu Gengfu Xiao Ke Lan Honglin Li Ke Xu | 2020 | Protein & Cell2020，11，10： | 14 |
| 2 | Early life migration and population discrimination of the small yellow croaker Larimichthys polyactis from the Yellow Sea: inferences from otolith Sr/Ca ratios显示文摘The small yellow croaker Larimichthys polyactis is a benthic marine fish species of high ecological and commercial importance and is widely distributed in the northwestern Pacifi c Ocean,especially in the Chinese coastal waters of the Bohai,Yellow,and East China Seas.As a highly migratory species,the whole life migration of L.polyactis has been intensively studied.However,knowledge about its early life migration is scarce,and population divisions are inconsistent,limiting the ability of fishery scientists and administrators to evaluate the design and potential benefits of thorough conservation and resource-management strategies.In the present study,otolith Sr/Ca was analyzed to investigate the early migratory patterns and discriminate the populations of L.polyactis in the Yellow Sea,including two spawning groups and one overwintering group.The variation in Sr/Ca ratios of ontogenetic growth zones,including the nucleus(N),larval(L),metamorphosis(M),juvenile(J),and edge(E)zones,was measured by electron probe microanalysis.The variation in Sr/Ca ratios in early developmental growth zones was generally characterized by an evident downward trend from the N to J zone,which suggests that the early migratory pattern of L.polyactis might be from inshore to nearshore water.Canonical discriminant analysis,based on the otolith Sr/Ca ratios of the N,L,M,and J zones,allowed the successful discrimination of the two populations,namely,the northern and southern Yellow Sea groups,whose diff erences were mainly reflected in the L and J zones.Compared with previous studies,the traditional geographic boundaries(34°N)separating these two populations might be moving northward.The application of otolith Sr/Ca ratios based on ontogenetic stage could improve our understanding of the migration and population discrimination of L.polyactis from the Yellow Sea. | Dade SONG Ying XIONG Tao JIANG Jian YANG Xiaming ZHONG Jianhua TANG | 2022 | Journal of Oceanology and Limnology2022，40，2： | 1 |
| 3 | The effect of ion implantation on the oxidation resistance of vacuum plasma sprayed CoNiCrA1Y coatings显示文摘 | Jiang Jie Zhao Huayu Zhou Xiaming | 2012 | Applied Surface Science2012，261，15： | 1 |
| 4 | Correction to:Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2显示文摘CORRECTION TO:PROTEIN CELL 2020,11(10):723–739 http://gffzzd3cc09b8251d45dfonu596wvqbnwn6bcp.ffgz.tsg.suse.edu.cn/10.1007/S13238-020-00768-W In the original publication the author’s name‘Dimitri Lavillete’is published incorrectly.The correct author name should be spelt as‘Dimitri Lavillette’is provided in this correction.OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License,which permits use,sharing,adaptation,distribution and reproduction in any medium or format,as long as you give appropriate credit to the original author(s)and the source,provide a link to the Creative Commons licence,and indicate if changes were made.The images or other third party material in this article are included in the article's Creative Commons licence,unless indicated otherwise in a credit line to the material.If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use,you will need to obtain permission directly from the copyright holder.To view a copy of this licence,visit http://gffzzeb6f7f563f66445dhnu596wvqbnwn6bcp.ffgz.tsg.suse.edu.cn/licenses/by/4.0/. | Rui Xiong Leike Zhang Shiliang Li Yuan Sun Minyi Ding Yong Wang Yongliang Zhao Yan Wu Weijuan Shang Xiaming Jiang Jiwei Shan Zihao Shen Yi Tong Liuxin Xu Yu Chen Yingle Liu Gang Zou Dimitri Lavillette Zhenjiang Zhao Rui Wang Lili Zhu Gengfu Xiao Ke Lan Honglin Li Ke Xu | 2022 | Protein & Cell2022，13，10： | 0 |
| 5 | Correction to: Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2显示文摘Figure 1.Discovery of novel and potent DHODHi and their anti-influenza A virus activities.(A)The discovery and design of S312 and S416.The detailed descriptions of the discovery workflow are in Method.Binding analysis of S312(B)and S416(C).Thermodynamic analysis of the binding of S312 and S416 to DHODH was carried out at 25 C on a MicroCal iTC200 instrument.Kinetic analysis of the binding of S312 and S416 to DHODH was performed with a Biacore T200 instrument. | Rui Xiong Leike Zhang Shiliang Li Yuan Sun Minyi Ding Yong Wang Yongliang Zhao Yan Wu Weijuan Shang Xiaming Jiang Jiwei Shan Zihao Shen Yi Tong Liuxin Xu Yu Chen Yingle Liu Gang Zou Dimitri Lavillete Zhenjiang Zhao Rui Wang Lili Zhu Gengfu Xiao Ke Lan Honglin Li Ke Xu | 2021 | Protein & Cell2021，12，1： | 0 |
| 6 | Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro显示文摘The recent outbreak of novel coronavirus pneumonia(COVID-19)caused by a new coronavirus has posed a great threat to public health.Identifying safe and effective antivirals is of urgent demand to cure the huge number of patients.Virusencoded proteases are considered potential drug targets.The human immunodeficiency virus protease inhibitors(lopinavir/ritonavir)has been recommended in the global Solidarity Trial in March launched by World Health Organization.However,there is currently no experimental evidence to support or against its clinical use.We evaluated the antiviral efficacy of lopinavir/ritonavir along with other two viral protease inhibitors in vitro,and discussed the possible inhibitory mechanism in silico.The in vitro to in vivo extrapolation was carried out to assess whether lopinavir/ritonavir could be effective in clinical.Among the four tested compounds,lopinavir showed the best inhibitory effect against the novel coronavirus infection.However,further in vitro to in vivo extrapolation of pharmacokinetics suggested that lopinavir/ritonavir could not reach effective concentration under standard dosing regimen[marketed as Kaletraò,contained lopinavir/ritonavir(200 mg/50 mg)tablets,recommended dosage is 400 mg/10 mg(2 tablets)twice daily].This research concluded that lopinavir/ritonavir should be stopped for clinical use due to the huge gap between in vitro IC50 and free plasma concentration.Nevertheless,the structure–activity relationship analysis of the four inhibitors provided further information for de novel design of future viral protease inhibitors of SARS-CoV-2. | Leike Zhang Jia Liu Ruiyuan Cao Mingyue Xu Yan Wu Weijuan Shang Xi Wang Huanyu Zhang Xiaming Jiang Yuan Sun Hengrui Hu Yufeng Li Gang Zou Min Zhang Lei Zhao Wei Li Xiaojia Guo Xiaomei Zhuang Xing-Lou Yang Zheng-Li Shi Fei Deng Zhihong Hu Gengfu Xiao Manli Wang Wu Zhong | 2020 | Virologica Sinica2020，35，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员